文献速递肿瘤 PET/CT放射性药物与辐射防护

[99mTc]Tc-PentixaTec:研发、广泛临床前评估及首次人体应用经验

[99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-08-19

研究基于PentixaFor骨架开发了一系列99mTc标记的环状五肽,其中[99mTc]Tc-N4-L6-CPCR4([99mTc]Tc-PentixaTec)在临床前显示最高CXCR4亲和力(IC50=0.6±0.1 nM)、最有效内化(2小时总细胞活性97%)和最高肿瘤摄取(8.6±1.3% iD/g,注射后1小时),后被用于5例血液系统恶性肿瘤患者的SPECT/平面显像及个体剂量测定,耐受良好,剂量为每500 MBq 2.1-3.4 mSv。

要点

  • [99mTc]Tc-PentixaTec对CXCR4亲和力高(IC50=0.6±0.1 nM),内化效率达2小时总细胞活性97%。
  • 临床前肿瘤摄取为8.6±1.3% iD/g(注射后1小时),SPECT/平面显像肿瘤/本底比值优良。
  • 5例血液系统恶性肿瘤患者中耐受良好,每500 MBq剂量为2.1-3.4 mSv。

核心结论

  • 对连接子氨基酸组成及N端99mTc标记策略(mas3 vs HYNIC vs N4)的逐步优化,使[99mTc]Tc-PentixaTec成为新型、极具前景的CXCR4靶向SPECT显像剂,具备优良的CXCR4亲和力、高效内化、在CXCR4表达组织中高摄取、合适的清除/生物分布特征和良好的人体剂量学,具有进一步临床应用的巨大潜力。

研究设计与样本

  • 合成6种mas3偶联的CPCR4类似物(含不同4-氨基苯甲酸(Abz)-D-Ala-D-Arg-aa3连接子L1-L6)及L6-CPCR4的HYNIC和N4类似物,用Jurkat T细胞淋巴瘤细胞和[125I]FC-131配体进行竞争结合研究(IC50和IC50inv),用过表达hCXCR4的Chem-1细胞研究内化动力学,用Jurkat异种移植瘤CB17/SCID小鼠进行生物分布研究和小动物SPECT/CT显像(注射后1小时)。
  • 基于临床前结果选择[99mTc]Tc-N4-L6-CPCR4([99mTc]Tc-PentixaTec)进行早期人体转化,5例血液系统恶性肿瘤患者接受[99mTc]Tc-N4-L6-CPCR4 SPECT/平面显像及个体剂量测定。

主要发现

  • 6种mas3偶联肽中,mas3-L6-CPCR4(mas3-dap-r-a-Abz-CPCR4)显示最高CXCR4亲和力(IC50=5.0±1.3 nM)。
  • 与N4偶联(N4-L6-CPCR4)使hCXCR4亲和力进一步提高至0.6±0.1 nM。
  • [99mTc]Tc-N4-L6-CPCR4内化效率最高(2小时总细胞活性97%),肿瘤摄取在所研究化合物中最高(8.6±1.3% iD/g,注射后1小时)。
  • [99mTc]Tc-PentixaTec耐受良好,生物分布和剂量学特征良好(每500 MBq 2.1-3.4 mSv),SPECT和平面显像肿瘤/本底比值优良。

关键数值与推荐

  • mas3-L6-CPCR4的CXCR4亲和力IC50=5.0±1.3 nM,N4-L6-CPCR4的hCXCR4亲和力IC50=0.6±0.1 nM。
  • [99mTc]Tc-N4-L6-CPCR4内化效率为2小时总细胞活性97%,肿瘤摄取为8.6±1.3% iD/g(注射后1小时)。
  • [99mTc]Tc-PentixaTec人体剂量为每500 MBq 2.1-3.4 mSv。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The clinical success non-invasive imaging of CXCR4 expression using [68 Ga]Ga-PentixaFor-PET warrants an expansion of the targeting concept towards conventional scintigraphy/SPECT with their lower cost and general availability. To this aim, we developed and comparatively evaluated a series of 99mTc-labeled cyclic pentapeptides based on the PentixaFor scaffold. METHODS: Six mas3-conjugated CPCR4 analogs with different 4-aminobenzoic acid (Abz)-D-Ala-D-Arg-aa3 linkers (L1-L6) as well as the corresponding HYNIC- and N4-analogs of L6-CPCR4 were synthesized via standard SPPS. Competitive binding studies (IC50 and IC50inv) were carried out using Jurkat T cell lymphoma cells and [125I]FC-131 as radioligand. Internalization kinetics were investigated using hCXCR4-overexpressing Chem-1 cells. Biodistribution studies and small animal SPECT/CT imaging (1 h p.i.) were carried out using Jurkat xenograft bearing CB17/SCID mice. Based on the preclinical results, [99mTc]Tc-N4-L6-CPCR4 ([99mTc]Tc-PentixaTec) was selected for an early translation to the human setting. Five patients with hematologic malignancies underwent [99mTc]Tc-N4-L6-CPCR4 SPECT/planar imaging with individual dosimetry. RESULTS: Of the six mas3-conjugated peptides, mas3-L6-CPCR4 (mas3-dap-r-a-Abz-CPCR4) showed the highest CXCR4 affinity (IC50 = 5.0 ± 1.3 nM). Conjugation with N4 (N4-L6-CPCR4) further improved hCXCR4 affinity to 0.6 ± 0.1 nM. [99mTc]Tc-N4-L6-CPCR4 also showed the most efficient internalization (97% of total cellular activity at 2 h) and the highest tumor accumulation (8.6 ± 1.3% iD/g, 1 h p.i.) of the compounds investigated. Therefore, [99mTc]Tc-N4-L6-CPCR4 (termed [99mTc]Tc-PentixaTec) was selected for first-in-human application. [99mTc]Tc-PentixaTec was well tolerated, exhibits a favorable biodistribution and dosimetry profile (2.1-3.4 mSv per 500 MBq) and excellent tumor/background ratios in SPECT and planar imaging. CONCLUSION: The successive optimization of the amino acid composition of the linker structure and the N-terminal 99mTc-labeling strategies (mas3 vs HYNIC vs N4) has provided [99mTc]Tc-PentixaTec as a novel, highly promising CXCR4-targeted SPECT agent for clinical application. With its excellent CXCR4 affinity, efficient internalization, high uptake in CXCR4-expressing tissues, suitable clearance/biodistribution characteristics, and favorable human dosimetry, it holds great potential for further clinical use.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Konrad M, Rinscheid A, Wienand G, et al. [99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience. Eur J Nucl Med Mol Imaging. 2023. PMID: 37597009. doi:10.1007/s00259-023-06395-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。